الصفحة الرئيسية>>Signaling Pathways>> DNA Damage/DNA Repair>> Antifolate>>LSN 3213128

LSN 3213128

رقم الكتالوجGC36486

LSN 3213128 هو مضاد انتقائي ، غير كلاسيكي ، متاح حيويًا عن طريق الفم مع نشاط مثبط قوي ومحدد لأمينو إيميدازول-4-كاربوكساميد ريبونوكليوتيد فورميل ترانسفيراز (AICARFT) ، مع IC50 من 16 نانومتر لمثبط إنزيم AICARFT و 19 نانومتر في الخلايانشاط مضاد للورم

Products are for research use only. Not for human use. We do not sell to patients.

LSN 3213128 التركيب الكيميائي

Cas No.: 1941211-99-9

الحجم السعر المخزون الكميّة
100mg Please Inquire Please Inquire
250mg Please Inquire Please Inquire
500mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

LSN 3213128 is a selective, nonclassical, orally bioavailable antifolate with potent and specific inhibitory activity for aminoimidazole-4-carboxamide ribonucleotide formyltransferase (AICARFT), with IC50 of 16 nM for AICARFT enzyme inhibiton and 19 nM in cells. Anti-tumor activity[1]. IC50: 16 nM (AICARFT), 19 nM (AICARFT in cells)[1]

[1]. Fales KR, et al. Discovery of N-(6-Fluoro-1-oxo-1,2-dihydroisoquinolin-7-yl)-5-[(3R)-3-hydroxypyrrolidin-1-yl]thiophene-2-sulfonamide (LSN 3213128), a Potent and Selective Nonclassical Antifolate Aminoimidazole-4-carboxamide Ribonucleotide Formyltransferase (AICARFT) Inhibitor Effective at Tumor Suppression in a Cancer Xenograft Model. J Med Chem. 2017 Dec 14;60(23):9599-9616.

مراجعات

Review for LSN 3213128

Average Rating: 5 ★★★★★ (Based on Reviews and 5 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for LSN 3213128

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.